5 results
10-Q
2023 Q3
NMRA
Neumora Therapeutics Inc.
1 Nov 23
Quarterly report
4:05pm
terminate the agreement upon 30 days’ written notice, subject to the Company paying reasonable costs incurred by Vanderbilt to wind-down the program
S-1
EX-3.1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any
S-1
EX-10.3
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
Licensed Compounds or Program Compounds other than RBNC Compounds:
RBNC will responsibly wind-down, in accordance with accepted pharmaceutical industry … of clarity, except as provided for above, RBNC may wind-down any ongoing clinical trials prior to the date of termination in accordance with accepted
S-1
EX-10.4
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
) or Section 9.4 (Termination Upon Bankruptcy), with respect to Products containing Licensed Compounds or Program Compounds:
RBNC will responsibly wind … at the
FTE Rate associated therewith. For the purpose of clarity, except as provided for above, RBNC may wind-down any ongoing clinical trials prior
DRS/A
EX-3.1
NMRA
Neumora Therapeutics Inc.
30 Jun 23
Draft registration statement (amended)
12:00am
or wind-up the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any
- Prev
- 1
- Next